Sign inJoin waitlistJoin the waitlist

Kristina Fanucci

Instructor in Medicine, Harvard Medical School · Mass General Brigham

Credentials: · · · · · ·

History

Mass General Brigham
Present

Yale University
2023–2025
Internal Medicine
Rhode Island Hospital/Brown University Health
2020–2023
Tufts University School of Medicine
2013–2017
Massachusetts Institute of Technology
2009–2013

Research

Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma
Cancer Research Communications · 2023 · Co-first of 16 authors · Corresponding · 32 citations
Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer
npj Breast Cancer · 2022 · 22 citations
Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone…
Review · ESMO Open · 2024 · First of 5 authors · 19 citations

Lajos Pusztai
3 papers
Sara Tolaney
3 papers
Alice Gottlieb
2 papers
Antonio Giordano
2 papers
DR
David Rimm
2 papers
Eric Sorensen
2 papers
Faina Nakhlis
2 papers
Filipa Lynce
2 papers
JB
Jennifer Bellon
2 papers
Rinath Jeselsohn
2 papers
SA
Shiu-Chung Au
2 papers
Abirami Sivapiragasam
1 paper

Clinical trials

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Principal investigator · Recruiting · Phase 2
Kristina A. Fanucci
2026–2030
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
Principal investigator · Recruiting · Phase 1, Phase 2
Kristina A. Fanucci
2025–2038